Results 11 to 20 of about 1,535,020 (310)

Budget Impact and Investment Case for HEARTS Hypertension Control Programs in 4 Low- and Middle-Income Countries [PDF]

open access: yesJACC: Advances
Background: Hypertension (HTN) is a leading modifiable risk factor for cardiovascular disease, yet diagnosis, treatment, and control are suboptimal in many low- and middle-income countries.
William Garcia, MSc   +11 more
doaj   +2 more sources

Budget Impact Analysis of Botulinum Toxin Type A for Patients with Severe Blepharospasm in Thailand [PDF]

open access: yesClinicoEconomics and Outcomes Research
Parima Hirunwiwatkul,1,2 Unchalee Permsuwan,3,4 Sureerat Ngamkiatphaisan,5 Niphon Chirapapaisan,6 Jiruth Sriratanaban7 1Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 2Department of Ophthalmology, King ...
Hirunwiwatkul P   +4 more
doaj   +2 more sources

Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective

open access: yesSaudi Pharmaceutical Journal, 2023
Costs of hemophilia A treatment are increasing. Waste of clotting products should be avoided. To estimate the first-year waste of emicizumab prophylaxis for people with hemophilia A and inhibitors (PwHAi) who failed immune tolerance induction (ITI), in ...
Ricardo Mesquita Camelo   +7 more
doaj   +1 more source

Budget based bonus, budget emphasis, budget gaming, and the impact on budget value [PDF]

open access: yesJurnal Keuangan dan Perbankan, 2020
The issue of budget value has received attention and criticism from many researchers, especially that the budget value is not aligned with the sacrifices made in the budgeting process. The purpose of the study is to examine the effect of budget-based bonus and budget emphasis towards budget gaming and its implications on budget value.
Rhaisya Setiawati Rachmat, SeTin SeTin
openaire   +2 more sources

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement

open access: yesFrontiers in Pharmacology, 2023
Legislations incentivising orphan drug development and scientific advances have made orphan drugs pharma’s high-end favourite for the past two decades. Currently, around 50% of new marketing authorizations are for orphan drugs. For third-party healthcare
Hans-Georg Eichler   +3 more
doaj   +1 more source

Transversal Budget Impact Analysis

open access: yes, 2023
109 p. ill., 1 INTRODUCTION 11 -- 1.1 CONTEXT 11 -- 1.2 AIM OF THE STUDY 13 -- 1.2.1 Research questions .13 -- 1.3 METHODS 14 -- 1.3.1 Two case studies 14 -- 1.3.2 Data sources analyzed 14 -- 1.3.3 Methods for the data analysis .15 -- 1.4 REPORT OUTLINE .17 -- 2 BACKGROUND 17 -- 2.1 THE GLOBAL AND PARTIAL BUDGETS OF THE FEDERAL RIZIV-INAMI ...
Camberlin, Cécile   +2 more
openaire   +3 more sources

Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension [PDF]

open access: yesТерапевтический архив, 2017
Aim. To provide a pharmacoeconomic estimate of macitentan versus bosentan in therapy for pulmonary arterial hypertension (PAH). Subject and methods. An analysis was carried out on the basis of a social perspective for patients, whose mean age was 50 ...
O M Moisseeva, A V Rudakova
doaj   +1 more source

Affordability of oncology drugs: accuracy of budget impact estimations

open access: yesJournal of Market Access & Health Policy, 2020
Background: In many countries, Budget Impact (BI) informs reimbursement decisions. Evidence has shown that decision-makers have restricted access based on high BI estimates but studies show that BI estimates are often inaccurate. Objective: To assess the
Joost W. Geenen   +4 more
doaj   +1 more source

The Energy Budgets of Giant Impacts [PDF]

open access: yesJournal of Geophysical Research: Planets, 2020
AbstractGiant impacts dominate the final stages of terrestrial planet formation and set the configuration and compositions of the final system of planets. A giant impact is believed to be responsible for the formation of Earth's Moon, but the specific impact parameters are under debate.
Carter, Philip   +2 more
openaire   +4 more sources

BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION

open access: yesФармакоэкономика, 2016
Objectives. To assess the incremental budget impact (BI) of using of utilizing perampanel to treat partial-onset seizures (POS) and primary generalized tonic-clonic seizures (PGTCS) in patients who are 12 years of age and older in Russia.Methods.
V. R. Mkrtchyan   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy